Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$7.95 +1.4%	$7.97	$5.15 ▼ $10.67	$1.07B	1.16	1.34 million shs	901,945 shs
MLYS Mineralys Therapeutics	$15.66 +0.5%	$14.40	$8.24 ▼ $18.38	$1.02B	-0.3	496,259 shs	268,305 shs
RCUS Arcus Biosciences	$9.21 +3.1%	$8.25	$6.50 ▼ $18.98	$974.67M	0.88	861,605 shs	903,075 shs
TRDA Entrada Therapeutics	$8.12 +6.8%	$8.35	$7.10 ▼ $21.79	$308.10M	0.04	132,594 shs	167,393 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	0.00%	-2.72%	-4.26%	-1.50%	+45.02%
MLYS Mineralys Therapeutics	0.00%	-1.44%	+2.01%	+75.95%	+23.18%
RCUS Arcus Biosciences	0.00%	-0.72%	-1.54%	-14.72%	-40.41%
TRDA Entrada Therapeutics	0.00%	+2.13%	-17.01%	-32.39%	-50.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	3.4016 of 5 stars	3.5	2.0	4.2	1.7	1.9
MLYS Mineralys Therapeutics	2.8393 of 5 stars	3.5	1.0	3.4	5.0	0.0
RCUS Arcus Biosciences	2.6393 of 5 stars	4.5	1.0	2.4	2.5	0.0
TRDA Entrada Therapeutics	2.7199 of 5 stars	3.6	2.0	2.4	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	44.64% Upside
MLYS Mineralys Therapeutics	3.00	Buy	$38.00	142.70% Upside
RCUS Arcus Biosciences	2.91	Moderate Buy	$25.67	178.83% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	216.17% Upside

Current Analyst Ratings Breakdown

Latest TRDA, AUPH, MLYS, and RCUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00
5/13/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00 ➝ $42.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
4/23/2025	RCUS Arcus Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $14.00
4/2/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$30.00 ➝ $42.00
3/31/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/10/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$247.30M	4.34	N/A	N/A	$2.63 per share	3.02
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A
RCUS Arcus Biosciences	$141M	6.91	N/A	N/A	$6.17 per share	1.49
TRDA Entrada Therapeutics	$172.22M	1.79	N/A	N/A	$7.26 per share	1.12

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	-$78.02M	$0.28	N/A	14.20	N/A	-10.23%	-4.41%	-3.07%	7/30/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-67.97%	-62.40%	8/12/2025 (Estimated)
RCUS Arcus Biosciences	-$307M	-$4.19	N/A	N/A	N/A	-102.66%	-45.59%	-22.38%	8/14/2025 (Estimated)
TRDA Entrada Therapeutics	-$6.68M	$0.81	5.11	N/A	N/A	25.53%	16.11%	10.39%	8/12/2025 (Estimated)

Latest TRDA, AUPH, MLYS, and RCUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.17	5.60	5.11
MLYS Mineralys Therapeutics	N/A	14.02	14.02
RCUS Arcus Biosciences	0.08	5.24	5.24
TRDA Entrada Therapeutics	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
MLYS Mineralys Therapeutics	84.46%
RCUS Arcus Biosciences	92.89%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
MLYS Mineralys Therapeutics	25.56%
RCUS Arcus Biosciences	12.30%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	137.02 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	33.27 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	80.26 million	Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.58 million	Optionable

TRDA, AUPH, MLYS, and RCUS Headlines

Recent News About These Companies

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.com

Entrada Therapeutics to start DMD trial in Q3 2025

May 29, 2025 | investing.com

Entrada Therapeutics Receives EU Authorization to Proceed with ELEVATE-45-201 Clinical Study for Duchenne Muscular Dystrophy, Set to Begin in Q3 2025

May 29, 2025 | nasdaq.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 28, 2025 | globenewswire.com

Q2 EPS Estimate for Entrada Therapeutics Raised by Analyst

May 24, 2025 | marketbeat.com

HC Wainwright Has Positive Forecast for TRDA Q2 Earnings

May 24, 2025 | americanbankingnews.com

What is HC Wainwright's Estimate for TRDA Q2 Earnings?

May 23, 2025 | marketbeat.com

Northern Trust Corp Has $5.50 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 23, 2025 | marketbeat.com

Q2 Earnings Forecast for TRDA Issued By HC Wainwright

May 23, 2025 | americanbankingnews.com

Entrada Therapeutics' (TRDA) "Buy" Rating Reaffirmed at HC Wainwright

May 23, 2025 | americanbankingnews.com

Entrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC Wainwright

May 22, 2025 | marketbeat.com

Janus Henderson Group PLC Acquires 368,908 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 17, 2025 | marketbeat.com

MPM Asset Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 16, 2025 | marketbeat.com

Q2 EPS Forecast for Entrada Therapeutics Reduced by Analyst

May 16, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Dimensional Fund Advisors LP

May 16, 2025 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results

May 12, 2025 | marketbeat.com

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

May 11, 2025 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Entrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other Candidates

May 2, 2025 | precisionmedicineonline.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Price T Rowe Associates Inc. MD

May 2, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, AUPH, MLYS, and RCUS Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$7.95 +0.11 (+1.42%)

Closing price 03:59 PM Eastern

Extended Trading

$7.96 +0.01 (+0.11%)

As of 04:04 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Mineralys Therapeutics NASDAQ:MLYS

$15.66 +0.08 (+0.49%)

Closing price 03:59 PM Eastern

Extended Trading

$15.69 +0.03 (+0.21%)

As of 04:04 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Arcus Biosciences NYSE:RCUS

$9.20 +0.28 (+3.08%)

Closing price 03:59 PM Eastern

Extended Trading

$8.94 -0.27 (-2.88%)

As of 04:09 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Entrada Therapeutics NASDAQ:TRDA

$8.12 +0.52 (+6.82%)

Closing price 03:59 PM Eastern

Extended Trading

$8.14 +0.02 (+0.21%)

As of 04:09 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time